All In Biotech

Drugs by condition

Drugs approved for osteoporosis

Brand-name prescription drugs and biologics whose FDA label lists osteoporosis as an approved use. Matched on the label phrases: "osteoporosis".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

29

Still marketed, NDA or BLA

Drug classes

7

Novel drugs

8

New molecular entities and new biologics

In development

4

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for osteoporosis.

  • Boncresa (Denosumab-Mobz) · Amneal Pharms LLC Dec 19, 2025
  • Denosumab-Dssb (Denosumab-Dssb) · Samsung Bioepis CO LTD Oct 29, 2025
  • Osvyrti (Denosumab-Desu) · Accord Biopharma Inc. Oct 29, 2025
  • Enoby (Denosumab-Qbde) · Hikma Pharmaceuticals USA INC Sep 26, 2025
  • Aukelso (Denosumab-Kyqq) · Biocon Biologics INC Sep 16, 2025

All approved drugs for osteoporosis, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 70 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

RANK Ligand Inhibitor (10)

  • Prolia Denosumab · Amgen · 2010
  • Boncresa Denosumab-Mobz · Amneal Pharms LLC · 2025
  • Denosumab-Dssb Denosumab-Dssb · Samsung Bioepis CO LTD · 2025
  • Osvyrti Denosumab-Desu · Accord Biopharma Inc. · 2025
  • Enoby Denosumab-Qbde · Hikma Pharmaceuticals USA INC · 2025
  • Aukelso Denosumab-Kyqq · Biocon Biologics INC · 2025
  • Bilprevda Denosumab-Nxxp · Shanghai Henlius Biotech · 2025
  • Conexxence Denosumab-Bnht · Fresenius Kabi USA LLC · 2025
  • Osenvelt Denosumab-Bmwo · Celltrion INC · 2025
  • Jubbonti Denosumab-Bbdz · Sandoz INC · 2024

Estrogen (8)

  • Duavee Bazedoxifene Acetate, Estrogens, Conjugated · Wyeth Pharms · 2013
  • Premarin Estrogens, Conjugated · Wyeth Pharms · 1942
  • Minivelle Estradiol · Noven · 2012
  • Climara Pro Estradiol, Levonorgestrel · Bayer Hlthcare · 2003
  • Activella Estradiol, Norethindrone Acetate · Amneal · 1998
  • Estradiol Estradiol · Sandoz · 1996
  • Prempro Estrogens, Conjugated, Medroxyprogesterone Acetate · Wyeth Pharms · 1995
  • Climara Estradiol · Bayer Hlthcare · 1994

Parathyroid Hormone Analog (2)

  • Bonsity Teriparatide · Alvogen · 2019
  • Forteo Teriparatide · Lilly · 2002

Parathyroid Hormone-Related Peptide Analog (1)

  • Tymlos Abaloparatide · Radius · 2017

Vitamin D (1)

  • Fosamax Plus D Alendronate Sodium, Cholecalciferol · Organon LLC · 2005

Calcitonin (1)

  • Miacalcin Calcitonin Salmon · Mylan Ireland LTD · 1986

Class not listed in FDA's data (6)

  • Evenity Romosozumab-Aqqg · Amgen INC · 2019
  • Actonel Risedronate Sodium · Apil · 1998
  • Evista Raloxifene Hydrochloride · Lilly · 1997
  • Fosamax Alendronate Sodium · Organon · 1995
  • Atelvia Risedronate Sodium · Apil · 2010
  • Reclast Zoledronic Acid · Sandoz · 2007

Drugs in development for osteoporosis

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • QL1206Phase 31 trial

    Qilu Pharmaceutical Co., Ltd. · Postmenopausal Women With Osteoporosis at High Risk of Fracture

  • QLG2128Phase 31 trial

    Qilu Pharmaceutical Co., Ltd. · Postmenopausal Women With Osteoporosis

  • AGA2118Phase 21 trial

    Angitia Biopharmaceuticals · Postmenopausal Osteoporosis

  • SAL056Phase 21 trial

    Shenzhen Salubris Pharmaceuticals Co., Ltd. · Postmenopausal Women With Osteoporosis

1 discontinued brand-name drugs whose label still names it

More on osteoporosis: recruiting trials · published research

Related in endocrinology and women's health: Hypothyroidism · Menopause symptoms · Endometriosis · Uterine fibroids · Birth control · Low testosterone · Growth hormone deficiency · Acromegaly · Cushing's syndrome

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.